SEC Form 4 · accession 0001209191-15-054768
BIODELIVERY SCIENCES INTERNATIONAL INC · BDSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francis E Odonnell Jr.
Director
Period of report
Jun 16, 2015
Accepted (ET)
Jun 18, 2015 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001103021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 16, 2015 | S | 50,000 | $8.03 | D | 1,950,490 | I | By HCG II, LLC |
| Common StockF4,F2,F3 | Jun 16, 2015 | J | 15,000 | — | D | 1,935,490 | I | By HCG II, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 16, 2015, Hopkins Capital Group II, LLC sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $8.03. The highest sale price for the Common Stock was $8.21 per share and the lowest sale price was $7.88 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2Represents all of the shares of the Issuer held by Hopkins Capital Group II, LLC ("HCGII").
- F3The shares are owned by HCGII. The Reporting Person is a discretionary beneficiary of an irrevocable spendthrift trust which directly owns a minority membership interest in HCGII. The Reporting Person disclaims ownership of all securities held by HCGII.
- F4The distribution was made to a consultant of HCGII, who is not an affiliate of the issuer and for no consideration.